Reuters logo
BRIEF-Neurotrope to provide detailed Alzheimer's drug data in coming months
2017年5月1日 / 下午2点01分 / 5 个月前

BRIEF-Neurotrope to provide detailed Alzheimer's drug data in coming months

May 1 (Reuters) - Neurotrope Inc-

* Neurotrope CEO says 1 patient on the 20 mcg arm and 3 on the 40 mcg arm dropped out of the study: conf call

* Neurotrope CSO: in this very seriously afflicted population, the rate of dropouts in the trial was typical: conf call

* Neurotrope CSO: stat significance in a phase 3 trial is usually defined by p value of 0.05, but this was a more exploratory phase 2 trial, and the data is encouraging

* Neurotrope CSO expects to provide more detailed results in coming months

* Neurotrope CEO says co is interested in finding a corporate partner to move forward with

* Neurotrope CSO: “we saw very modest efficacy from the 40 mcg” Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below